The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke: The CLEAR Stroke Trial
Open accessAbstract
Background and Purpose— Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The c ombined approach to l ysis utilizing e ptifibatide a nd r ecombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination. Methods— The CLEAR trial was a National Institutes of Health/National Institute of Neurological Disorders and Stroke–funded multicenter, double-blind, randomized, dose-escalation and safety study. Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg). The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours. Secondary analyses were performed regarding clinical efficacy. Results— Ninety-four patients (40 in tier 1 and 54 in tier 2) were enrolled. The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 ( P =0.01 for NIHSS score). Fifty-two (75%) of the combination treatment group and 24 (96%) of the standard treatment group had a baseline modified Rankin scale score of 0 ( P =0.04). There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA–only arm ( P =0.17). During randomization in tier 2, a review by the independent data safety monitoring board demonstrated that the safety profile of combination therapy at the tier 2 doses was such that further enrollment was statistically unlikely to indicate inadequate safety for the combination treatment group, the ultimate outcome of the study. Thus, the study was halted. There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group. Conclusions— The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Self-citationPowers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Self-citationPowers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Self-citationLees, K. R., Bluhmki, E., von Kummer, R., Brott, T. G., Toni, D., Grotta, J. C., Albers, G. W., Kaste, M., Marler, J. R., Hamilton, S. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60491-6 · Cited by 2,184
Self-citationThrombolysis for acute ischaemic stroke
Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000213.pub3 · Cited by 1,370
Self-citationEuropean Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A. C., Padiglioni, C., Pérez de la Ossa, N., Strbian, D., Tsivgoulis, G., & Turc, G. (2021) · European Stroke Journal · doi:10.1177/2396987321989865 · Cited by 1,355
Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., et al. (2016) · Stroke · doi:10.1161/str.0000000000000086 · Cited by 670
“However, a previous randomized trial of abciximab for acute ischemic stroke was terminated early because of an increased risk of sICH compared with placebo, suggesting that there could be safety concerns.(451)”
BackgroundSelf-citationWeitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Weintraub, N. L., Collins, S. P., Pang, P. S., Levy, P. D., Anderson, A. S., Arslanian-Engoren, C., Gibler, W. B., McCord, J. K., Parshall, M. B., Francis, G. S., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181f9a223 · Cited by 274
Prabhakaran, S., Gonzalez, N. R., Zachrison, K. S., Adeoye, O., Alexandrov, A. W., Ansari, S. A., Chapman, S., Czap, A. L., Dumitrascu, O. M., Ishida, K., et al. (2026) · Stroke · doi:10.1161/str.0000000000000513 · Cited by 273
Self-citationFactors influencing haemorrhagic transformation in ischaemic stroke
Álvarez-Sabín, J., Maisterra, O., Santamarina, E., & Kase, C. S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70055-3 · Cited by 270
Metadata
- Authors
- Pancioli, A. M., Broderick, J., Brott, T., Tomsick, T., Khoury, J., Bean, J., del Zoppo, G., Kleindorfer, D., Woo, D., Khatri, P., Castaldo, J., Frey, J., Gebel, J., Kasner, S., Kidwell, C., Kwiatkowski, T., Libman, R., Mackenzie, R., Scott, P., Starkman, S., & Thurman, R. J.
- Venue
- Stroke
- Published
- 2008-12
- Volume
- 39
- Issue
- 12
- Pages
- 3268-3276
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2107321252
- Cited by
- 187
- References
- 1
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.